Apyx Medical Inc

Apyx Medical Corporation reported second-quarter 2026 total revenue of $13.9 million, a 22% increase from the prior year, driven by 28% growth in its Surgical Aesthetics segment. Surgical Aesthetics revenue reached $12.4 million, fueled by sales of the AYON Body Contouring System, increased international generator sales, and higher domestic single-use handpiece volume, while OEM segment revenue declined 12% to $1.5 million. Net loss attributable to stockholders narrowed to $3.2 million, or $0.07 per share, from $3.8 million, or $0.09 per share, and adjusted EBITDA loss improved to $0.7 million from $2.0 million. The company reaffirmed its full-year 2026 total revenue guidance of $59.0 million to $60.0 million, with Surgical Aesthetics expected to contribute $54.0 million to $55.0 million and OEM approximately $5.0 million. Apyx Medical also highlighted the limited launch of a power liposuction handpiece for the AYON platform following expanded FDA clearance, with initial commercial shipments in June 2026.

Apyx Medical Corporation announced new clinical data showing that a combination treatment using its Avéli and Renuvion devices improved cellulite in 81.8% of patients. The study, published in Aesthetic Surgery Journal Open Forum, involved 22 patients and used 3D imaging to measure reductions in dimple volume. The approach pairs Avéli for targeted subcision of fibrous septae with Renuvion's controlled helium plasma radiofrequency energy to reduce skin laxity. Lead investigator Barry E. DiBernardo, MD, said the findings add to growing evidence supporting complementary treatment approaches.